Recent developments for Aethlon Medical include reaffirmation of regulatory engagement plans for the Hemopurifier, a $4.5 million public offering of common stock and warrants, patent grants for Hemopurifier use in Long COVID and coagulopathy treatments, and updates on clinical trial progress and financial condition.

• In May 2026, Aethlon Medical reaffirmed its regulatory engagement plans for the Hemopurifier, supporting ongoing clinical development efforts [N1].
• In September 2025, the company priced a $4.5 million public offering of common stock and warrants to support working capital and clinical activities [N3][N4].
• In September 2025, Aethlon secured patents for Hemopurifier use in Long COVID and coagulopathy-associated conditions, expanding potential applications [N5].
• In August 2025, the company reported a reduction in fiscal Q1 losses, reflecting operational adjustments [N6].
• In June 2025, insider trading and hedge fund activity were noted ahead of earnings, indicating market interest [N7].
• In January 2025, Aethlon treated the first patient in its Hemopurifier cancer trial in Australia, marking a clinical milestone [N8].
• In February 2026, concerns were raised about financial struggles, stockholder dilution, and market challenges facing the company [N2].

The Hemopurifier's unique mechanism targeting extracellular vesicles and enveloped viruses addresses unmet medical needs in oncology and infectious diseases. The FDA Breakthrough Device designations for cancer and viral indications highlight regulatory support. Ongoing clinical trials in Australia and prior human studies provide safety and preliminary efficacy data. The company's expanding patent portfolio and manufacturing capabilities position it to advance development and potential commercialization. Recent patent grants for Long COVID and coagulopathy applications may broaden the device's utility. Successful clinical and regulatory milestones could enable Aethlon to establish a novel therapeutic platform in challenging disease areas.

Aethlon Medical faces significant challenges as a clinical-stage company with no approved products or commercial sales. The Hemopurifier requires successful completion of clinical trials and regulatory approvals, which are subject to delays and uncertainties, including potential impacts from FDA funding and staffing constraints. Manufacturing depends on qualified suppliers and regulatory approvals, with risks of supply disruptions. The company has reported substantial net losses and limited cash reserves, necessitating additional capital raises that may dilute shareholders. Competition from established pharmaceutical and medical device companies could limit market penetration. The absence of current sales and marketing infrastructure adds to commercialization risks. Preclinical findings and exploratory research may not translate into clinical benefits.

Aethlon Medical's moat is based on its proprietary Hemopurifier technology, which utilizes a unique lectin-affinity mechanism to remove enveloped viruses and extracellular vesicles implicated in multiple disease states. The company holds a portfolio of issued patents and pending applications worldwide protecting this technology and related therapeutic methods. The Hemopurifier has received FDA Breakthrough Device designation for two distinct indications, reflecting regulatory recognition of its novel approach. Clinical data demonstrating safety and viral clearance in human studies further support its differentiation. However, as a clinical-stage device without commercial sales, the moat is contingent on successful regulatory approvals, manufacturing scale-up, and market adoption in competitive therapeutic areas.

• Regulatory Approval Risks: The Hemopurifier requires FDA and other regulatory approvals before commercialization. Delays or failures in clinical trials or regulatory reviews could impede product development and market entry.
• Financial Risks: The company has reported net losses and limited cash reserves. Continued operations depend on raising additional capital, which may dilute existing shareholders and impact financial stability.
• Manufacturing and Supply Chain Risks: Manufacturing relies on qualified suppliers and regulatory approvals. Delays in supplier qualification or disruptions could affect production and clinical trial supply.
• Competitive Risks: The medical device and therapeutic markets are competitive, with established players. The Hemopurifier must demonstrate clinical benefits and cost-effectiveness to gain adoption.
• Operational Risks: Aethlon currently lacks sales and marketing capabilities, which may delay commercialization. The company also depends on a small number of employees and consultants.
• Regulatory Environment Risks: Changes in FDA funding, staffing, or regulatory policies, including government shutdowns, may delay reviews and approvals critical to the company's development programs.

• Aethlon Medical, Inc. is a clinical-stage medical therapeutic company focused on developing the Hemopurifier, an investigational immunotherapeutic device designed to remove enveloped viruses and extracellular vesicles (EVs) from biological fluids.
• The Hemopurifier uses proprietary lectin-based technology to bind and remove enveloped viruses and EVs, which are implicated in cancer progression, immune suppression, and severe infectious diseases.
• The device has been evaluated in human studies involving 173 treatment sessions in 44 patients with viral infections or cancer, showing a safety profile consistent with extracorporeal therapy and evidence of viral clearance.
• The FDA has granted the Hemopurifier Breakthrough Device designation for two indications: treatment of advanced/metastatic cancer unresponsive or intolerant to standard therapy, and treatment of life-threatening viruses without approved therapies.
• Aethlon is conducting a safety, feasibility, and dose-finding clinical trial in Australia for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment; enrollment and treatment of initial cohorts have been completed with no serious adverse events related to the device.
• The company previously received approval for a similar oncology trial in India but chose not to proceed to conserve resources and focus on the Australian trial.
• The Hemopurifier has been used under emergency and investigational protocols to treat patients with Ebola, HIV, Hepatitis C, and COVID-19, demonstrating viral load reductions and safety in small-scale studies.
• The company maintains an open IDE for viral indications, allowing treatment in the US and Canada under Expanded Access protocols for Ebola virus infection.
• Preclinical studies have demonstrated the Hemopurifier's ability to remove platelet-derived extracellular vesicles implicated in various diseases including cancer, lupus, multiple sclerosis, Alzheimer's, sepsis, acute and Long COVID.
• Aethlon has published preclinical research on the Hemopurifier's potential applications in Long COVID and coagulopathy associated conditions, though these findings are exploratory and not clinical outcomes.
• The company has initiated manufacturing of the Hemopurifier at its San Diego facility under cGMP conditions, with FDA approval to begin manufacturing but is awaiting approval for a second supplier of a key component.
• Aethlon has a patent portfolio of approximately 19 issued patents and 18 pending applications worldwide related to extracorporeal removal technologies and therapeutic methods.
• As of March 31, 2026, the company had cash and equivalents of approximately $5.0 million, current assets of $5.57 million, current liabilities of $1.45 million, resulting in a current ratio of 3.85 and a cash ratio of 3.47, indicating liquidity.
• For fiscal year ended March 31, 2026, the company reported a net loss of approximately $7.15 million and basic and diluted EPS of -$10.61 per share.
• Aethlon has no sales and marketing capabilities currently and intends to build or contract these functions upon product approval.
• The company has 9 full-time employees as of June 8, 2026, all located in the United States, and uses consultants to conserve resources.
• Recent developments include a $4.5 million public offering of common stock and warrants in September 2025 and ongoing regulatory engagement for the Hemopurifier.
• The company faces risks including regulatory approval delays, manufacturing supply chain dependencies, financial constraints, and competitive pressures in the medical device and therapeutic markets.
• The FDA and other regulatory agencies' funding and staffing levels, including government shutdowns, may impact the timing of regulatory reviews and approvals relevant to Aethlon's clinical development and commercialization efforts.